News | Nuclear Imaging | December 12, 2016

Response of Colorectal Cancer to Treatment Can Be Detected as Early as One Day After a Single Administration of Drug

Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be detected with their innovative diagnostic agent (Tc-99m duramycin-TumorVue) as early as one day after a single administration of drug. Results from this preclinical study were published online.

“Although imaging agents such as 18F-FDG show great promise as biomarkers for early response to targeted cancer therapy, conflicting results are reported after immunotherapy. If our preclinical findings can be confirmed in patients, TumorVue has the potential to fill this gap since it does not seem to be hampered by the presence or absence of an inflammatory response,” said Professor Sigrid Stroobants of the Antwerp University Hospital (UZA).

“Detection of early treatment response will allow for improved management of cancer patients in the clinic. This study demonstrated that TumorVue™ enables readout of tumor response to targeted therapy as early as one day after start of treatment,” said Dr. Leonie Wyffels at the University of Antwerp’s Molecular Imaging Center Antwerp (UAntwerp-MICA). “The superiority of TumorVue™ over 18F-FDG for early detection of treatment response in colorectal tumors is exciting.”

Chris Pak, president and CEO of MTTI said, “We are encouraged by the results of TumorVue for detection of treatment response to targeted therapy as early as one day. Our goal is to translate these findings into patients to differentiate responders from non-responders. This innovative agent will be a powerful tool for personalized medicine where cancer patients will be spared the toxicity of ineffective therapy.”

For more information: www.uantwerp.be

Related Content

University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017
IBA Molecular announced that it has merged with previous acquisition Mallinckrodt Nuclear Medicine LLC to form the new...
FDG-PET, cell mutations, lung cancer patients, non-small cell lung cancer, NSCLC, Journal of Nuclear Medicine study

From left to right are patients with EGFR mutation, KRAS mutation, and EGFR– and KRAS– tumors, respectively. Stage I and III tumors are shown in the top and bottom rows, respectively. Arrows indicate the locations of the lung tumors. Credit: Stephen S.F. Yip, Ph.D., and Hugo Aerts, Ph.D., Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston; John Kim, M.D., University of Michigan Health System, Ann Arbor, Mich.

News | PET Imaging | April 05, 2017
Researchers have used positron emission tomography (PET) to successfully identify genetic cell mutations that can cause...
GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017
GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered in Nashville,...
Northwestern Memorial Hospital, MR-PET scanner, first in Illinois, Siemens Biograph mMR
News | PET-MRI | March 31, 2017
Northwestern Memorial Hospital is now home to the Chicago area's first combined magnetic resonance (MRI) and positron...
News | Radiopharmaceuticals and Tracers | March 29, 2017
Advanced Accelerator Applications S.A. announced that its product NETSPOT (gallium Ga-68 dotatate) has been included in...
PET/CT, recurrent prostate cancer, fluciclovine F-18, Emory University

CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.

News | Radiopharmaceuticals and Tracers | March 16, 2017
The featured clinical investigation article of the March 2017 issue of the Journal of Nuclear Medicine demonstrates...
FDG PET/CT, lung cancer, radiation therapy, AJR study, American Journal of Roentgenology
News | Lung Cancer | March 13, 2017
FDG positron emission tomography/computed tomography (PET/CT) is a valuable imaging tool for treatment assessment of...
Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers | March 10, 2017 | Anamika Kumari
Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial r
X0000_Piramal_Neuraceq PET agent_beta amyloid plaque imaging.jpg
News | Radiopharmaceuticals and Tracers | March 09, 2017
March 9, 2017 — Piramal Imaging SA and Isologic Innovative Radiopharmaceuticals recently announced that Health Canada
Overlay Init